Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Leslie A. Andritsos, MD, Mirela Anghelina, MD, Nicole R. Grieselhuber, MD PhD, Sameek Roychowdhury, MD PhD, Julie Reeser, PhD, Cynthia Timmers, PhD, Aharon G. Freud, MD PhD, James S. Blachly, MD, David M. Lucas, PhD, Gerard Lozanski, MD, Jeffrey Jones, MD MPH, Kerry A. Rogers, MD, Weiqiang Zhao, MD PhD, Michael R. Grever, MD

Blood (2016) 128 (22): 5598.

https://doi.org/10.1182/blood.V128.22.5598.5598

Published: 2016

Journal Articles

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

Evgeny Arons, PhD, Laura Roth, Sharon Adams, CHS, Jeffery Sapolsky, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2012) 120 (21): 2488.

https://doi.org/10.1182/blood.V120.21.2488.2488

Published: 2012

Journal Articles

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Waleed Haso, M.S., Daniel W. Lee, III, MD, Ira Pastan, MD, Dimiter S. Dimitrov, Ph.D, Crystal L Mackall, MD, Rimas J Orentas, PhD

Blood (2012) 120 (21): 2611.

https://doi.org/10.1182/blood.V120.21.2611.2611

Published: 2012

Journal Articles

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Rimas J Orentas, PhD, Waleed Haso, B.S., Richard A. Morgan, Ira Pastan, MD, Crystal L Mackall, MD

Blood (2011) 118 (21): 4313.

https://doi.org/10.1182/blood.V118.21.4313.4313

Published: 2011

Journal Articles

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Alan Wayne, MD, Deepa Bhojwani, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PHD, Lewis B. Silverman, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 3246.

https://doi.org/10.1182/blood.V116.21.3246.3246

Published: 2010

Journal Articles

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Robert J. Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H. Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 2516.

https://doi.org/10.1182/blood.V116.21.2516.2516

Published: 2010

Journal Articles

Bryostatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy.

Ingo Ringshausen, Thomas Decker, Viola Biberacher, Christian Meyer zum Buschenfelde, Madlen Oelsner, Michaela Wagner, Christian Bogner, Christian Peschel, MD

Blood (2009) 114 (22): 3429.

https://doi.org/10.1182/blood.V114.22.3429.3429

Published: 2009

Journal Articles

Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.

Robert J Kreitman, MD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Ira Pastan, MD

Blood (2009) 114 (22): 3442.

https://doi.org/10.1182/blood.V114.22.3442.3442

Published: 2009

Journal Articles

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

Alan S. Wayne, MD, Deepa Bhojwani, MD, Sima Jeha, MD, Maryalice Stetler-Stevenson, MD, PhD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, Robert J Kreitman, MD, Karen Kaucic, MD, Ira Pastan

Blood (2009) 114 (22): 839.

https://doi.org/10.1182/blood.V114.22.839.839

Published: 2009

Journal Articles

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Robert J Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert Lechleider, MD, Karen Kaucic, MD, Ira Pastan, MD

Blood (2009) 114 (22): 888.

https://doi.org/10.1182/blood.V114.22.888.888

Published: 2009

Journal Articles

Interim Phase I Results of Recombinant Immunotoxin HA22 in Patients with Hairy Cell and Chronic Lymphocytic Leukemias

Robert J. Kreitman, MD, Wyndham H. Wilson, Maryalice Stetler-Stevenson, Pierre Noel, David J FitzGerald, Ira Pastan

Blood (2008) 112 (11): 3160.

https://doi.org/10.1182/blood.V112.11.3160.3160

Published: 2008

Journal Articles

Soluble CD22 as a tumor marker for hairy cell leukemia

Kakushi Matsushita, Inger Margulies, Masanori Onda, Satoshi Nagata, Maryalice Stetler-Stevenson, Robert J. Kreitman

Blood (2008) 112 (6): 2272–2277.

https://doi.org/10.1182/blood-2008-01-131987

Published: 2008

Journal Articles

Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).

Yachna Ahuja, BS, Maryalice Stetler-Stevenson, MD/PhD, Robert J. Kreitman, MD, Ira Pastan, MD, Alan S. Wayne, MD

Blood (2007) 110 (11): 865.

https://doi.org/10.1182/blood.V110.11.865.865

Published: 2007

Journal Articles

Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).

Alan S. Wayne, MD, Harry W. Findley, PhD, Glen Lew, MD, Yachna Ahuja, BS, Lubing Gu, MD, Maryalice Stetler-Stevenson, MD, PhD, Robert J. Kreitman, MD, Ira Pastan, MD

Blood (2007) 110 (11): 855.

https://doi.org/10.1182/blood.V110.11.855.855

Published: 2007

Journal Articles

BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.

Thomas Decker, M.D., Michaela Wagner, Madlene Oelsner, Robert J. Kreitman, M.D., Ira Pastan, M.D., Christian Peschel, M.D., Thomas Licht, M.D.

Blood (2004) 104 (11): 4613.

https://doi.org/10.1182/blood.V104.11.4613.4613

Published: 2004

Journal Articles

Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins

Thomas Decker, Madlene Oelsner, Robert J. Kreitman, Giuliana Salvatore, Qing-cheng Wang, Ira Pastan, Christian Peschel, Thomas Licht

Blood (2004) 103 (7): 2718–2726.

https://doi.org/10.1182/blood-2003-04-1317

Published: 2004

NARROW

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Bryostatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy.

Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Interim Phase I Results of Recombinant Immunotoxin HA22 in Patients with Hairy Cell and Chronic Lymphocytic Leukemias

Soluble CD22 as a tumor marker for hairy cell leukemia

Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).

Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).

BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.

Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only